연구성과로 돌아가기
2024 연구자 정보 (42 / 1079)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Anderson, Katie (Anderson, K) |
Vaccitech, Harwell, Oxon, South Korea |
|
|
[JCR상위 1.7] Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | tom.evans@barinthusbio.com; | ||
|
Arai, Yasuaki (Arai, Y) |
Natl Canc Ctr, Dept Diagnost Radiol, Chuo Ku, Tokyo, Japan |
|
|
[JCR상위 1.7] EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. [JCR상위 1.7] mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma |
SCIE | 1.7 |
ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY |
bsangro@unav.es; | ||
|
Bae, Ki Beom (Bae, KB) |
|
|
[JCR상위 1.7] Early versus conventional adjuvant chemotherapy in stage III colon cancer: A multicenter, randomized, open-label, phase 3 trial | SCIE | 1.7 | ONCOLOGY | ||||
|
Bae, Sung Uk (Bae, SU) |
JXL-8219-2024 Kim, Sung-Bae |
|
[JCR상위 1.7] Early versus conventional adjuvant chemotherapy in stage III colon cancer: A multicenter, randomized, open-label, phase 3 trial | SCIE | 1.7 | ONCOLOGY | ||||
|
Baek, Seong Kyu (Baek, SK) |
|
|
[JCR상위 1.7] Early versus conventional adjuvant chemotherapy in stage III colon cancer: A multicenter, randomized, open-label, phase 3 trial | SCIE | 1.7 | ONCOLOGY | ||||
|
Baek, Sun Kyung (Baek, SK) |
Kyung Hee Univ Hosp, Seoul, South Korea Kyung Hee Univ, Med Ctr, Dept Internal Med, Seoul, South Korea |
|
|
[JCR상위 1.7] A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial. [JCR상위 27.1] A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15) |
SCIE | 1.7 | ONCOLOGY | oncolee@ewha.ac.kr;yhparkhmo@skku.edu; | ||
|
Bair, Ming-Jong (Bair, MJ) |
Mackay Mem Hosp, Taichung, Taiwan |
|
|
[JCR상위 1.7] Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | limys@amc.seoul.kr; | ||
|
Barnes, Ellie (Barnes, E) |
Univ Oxford, Nuffield Dept Med, Oxford, England Oxford Univ Hosp NHS Trust, NIHR Oxford Biomed Res Ctr, Oxford, England |
|
0000-0002-0860-0831 Barnes, Eleanor |
[JCR상위 1.7] Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | tom.evans@barinthusbio.com; | ||
|
Beom, Seung-Hoon (Beom, SH) |
Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Internal Med, Seoul, South Korea |
|
0000-0001-7036-3753 Beom, Seung-Hoon |
[JCR상위 1.7] Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY | SCIE | 1.7 | ONCOLOGY | ykkang@amc.seoul.kr; | ||
|
Bontempi, Elza (Bontempi, E) |
Univ Brescia, Dept Mech & Ind Engn, INSTM & Chem Technol Lab, Via Branze 38, I-25123 Brescia, Italy |
F-3216-2010 Bontempi, Elza |
0000-0003-1656-7506 Bontempi, Elza |
[JCR상위 1.7] Skin protection from solar ultraviolet radiation using natural compounds: a review | SCIE | 1.7 | CHEMISTRY, MULTIDISCIPLINARY;ENVIRONMENTAL SCIENCES;ENGINEERING, ENVIRONMENTAL | ankit.verma@mail.huji.ac.il;alessandra.zanoletti@unibs.it;2021321530@knu.ac.kr;adelodun.b@unilorin.edu.ng;kumarpankajgkv@gmail.com;foajibade@futa.edu.ng;lsilva8@cuc.edu.co;ankurphillips245@gmail.com;tkarthees@gmail.com;elza.bontempi@unibs.it;ashish.dwivedi1@iitr.res.in; | ||
|
Bouattour, Mohamed (Bouattour, M) |
Hop Beaujon, AP HP, Med Oncol, Paris, France |
|
|
[JCR상위 1.7] EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. [JCR상위 1.7] mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma |
SCIE | 1.7 |
ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY |
bsangro@unav.es; | ||
|
Braman, Nathaniel (Braman, N) |
|
|
[JCR상위 1.7] An interpretable AI-derived radiology signature to identify patients at risk of progression on the PACIFIC regimen for unresectable non-small cell lung cancer [JCR상위 1.7] CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC) [JCR상위 1.7] AI-based radiomics model for predicting immune checkpoint inhibitor-related pneumonitis (CIP) in patients with advanced NSCLC: An external validation study |
SCIE | 1.7 | ONCOLOGY | ||||
|
Brown, Anthony (Brown, A) |
Univ Oxford, Nuffield Dept Med, Oxford, England |
|
|
[JCR상위 1.7] Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | tom.evans@barinthusbio.com; | ||
|
Bussey, Louise (Bussey, L) |
Vaccitech, Harwell, Oxon, South Korea |
|
|
[JCR상위 1.7] Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | tom.evans@barinthusbio.com; | ||
|
Cantor, Diego (Cantor, D) |
|
|
[JCR상위 1.7] An interpretable AI-derived radiology signature to identify patients at risk of progression on the PACIFIC regimen for unresectable non-small cell lung cancer | SCIE | 1.7 | ONCOLOGY |
페이지 이동: